Markets

Strength Seen in Inovio (INO): Stock Rises 9.4% - Tale of the Tape

Inovio Pharmaceuticals, Inc. ( INO ) was a big mover last session with its shares rising over 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company as the stock is now trading above the past one month's volatile price range of $8.00 to $9.85.

This biotechnology company focusing on cancers and infectious diseases has seen no estimate revision in the last 7 days. The Zacks Consensus Estimate hasn't been in a trend either. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Inovio currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.

Investors interested in the biomedical industry may consider stocks like ANI Pharmaceuticals, Inc. ( ANIP ), Gilead Sciences Inc. ( GILD ) and Illumina Inc. ( ILMN ). All the three stocks sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

INOVIO PHARMAC (INO): Free Stock Analysis Report

ANI PHARMACEUT (ANIP): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

ILLUMINA INC (ILMN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GILD ANIP INO ILMN

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More